Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2017 Summary According to the recently published report 'Retinoic Acid Receptor Gamma - Pipeline Review, H2 2017'; Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close to 18 molecules. Out of which approximately 18 molecules are developed by Companies. Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development. The report 'Retinoic Acid Receptor Gamma - Pipeline Review, H2 2017' outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 1, 7 and 1 respectively. Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Immunology, Ophthalmology, Respiratory, Gastrointestinal, Genetic Disorders and Oncology which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Allergies, Autoimmune Disorders, Congenital Ichthyosis, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Gorlin Syndrome (Basal Cell Nevus Syndrome), Head And Neck Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis sicca (Dry Eye), Multiple Hereditary Exostoses, Psoriasis and Retinopathy Of Prematurity. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects - The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview 7 Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 11 Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment 14 Assessment by Mechanism of Action 14 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development 20 3SBio Inc 20 Boehringer Ingelheim GmbH 20 Clementia Pharmaceuticals Inc 20 Galderma SA 21 Lee's Pharmaceutical Holdings Ltd 22 Phosphagenics Ltd 22 Promius Pharma LLC 22 Sol-Gel Technologies Ltd 23 Valeant Pharmaceuticals International Inc 23 Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles 25 (adapalene + clindamycin hydrochloride) - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 (benzoyl peroxide + tretinoin) - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 (clindamycin phosphate + tretinoin) - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 adapalene + benzoyl peroxide + clindamycin phosphate - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 alitretinoin - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 bexarotene + CD1530 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 palovarotene - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Small Molecule to Antagonize ROR-Gamma for Autoimmune and Allergic Disorders - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecules to Agonize RARG for Fibrosis - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 tazarotene - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 tazoretene - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 TPX-6001 + tretinoin - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 tretinoin - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 tretinoin - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 trifarotene - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 vitamin A palmitate - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 vitamin A palmitate - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products 53 Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued Products 55 Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones 56 Featured News & Press Releases 56 Aug 31, 2017: Clementia Announces Data Presentations at Upcoming Medical Conferences in September 56 Jul 20, 2017: Sol-Gel Announces Positive Phase 2 Clinical Trial Results for TWIN in Patients with Acne Vulgaris 57 Jun 05, 2017: Clementia Pharmaceuticals to Host Symposium at the 8th International Conference on Children's Bone Health 57 Mar 28, 2017: Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive Trends 58 Oct 14, 2016: Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva 59 Aug 08, 2016: Clementia Clinical Program: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study 60 Jun 13, 2016: Clementia Clinical Program: Next Step in Clementia's Clinical Program for Fibrodysplasia Ossificans Progressiva (FOP) 60 Jun 09, 2016: Galderma Trifarotene Development Program Meets Key Milestone for Lamellar Ichthyosis Orphan Disease 61 Apr 23, 2016: Clementia Pharmaceuticals Joins Global FOP Community in Recognizing Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day 62 Apr 14, 2016: Positive Effects of Palovarotene on Spontaneous Heterotopic Ossification, Mobility, and Skeletal Growth in Mouse Models of FOP Reported in Journal of Bone and Mineral Research 63 Feb 29, 2016: Clementia Announces Last Patient Enrolled in Phase II trial of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva 64 Jan 21, 2016: GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program 64 Aug 25, 2015: Clementia Pharmaceuticals Expands Ongoing Phase 2 Study to Include Children with Fibrodysplasia Ossificans Progressiva 65 May 28, 2015: Clementia Advances Natural History Study of Patients with Fibrodysplasia Ossificans Progressiva 65 Apr 02, 2015: Clementia Advances Phase 2 Clinical Trial of Palovarotene in Fibrodysplasia Ossificans Progressiva Based on Recommendations from Data Monitoring Committee 66 Appendix 68 Methodology 68 Coverage 68 Secondary Research 68 Primary Research 68 Expert Panel Validation 68 Contact Us 68 Disclaimer 69
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indication, H2 2017 10 Number of Products under Development by Companies, H2 2017 11 Products under Development by Companies, H2 2017 12 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13 Number of Products by Stage and Mechanism of Actions, H2 2017 15 Number of Products by Stage and Route of Administration, H2 2017 17 Number of Products by Stage and Molecule Type, H2 2017 19 Pipeline by 3SBio Inc, H2 2017 20 Pipeline by Boehringer Ingelheim GmbH, H2 2017 20 Pipeline by Clementia Pharmaceuticals Inc, H2 2017 21 Pipeline by Galderma SA, H2 2017 21 Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017 22 Pipeline by Phosphagenics Ltd, H2 2017 22 Pipeline by Promius Pharma LLC, H2 2017 23 Pipeline by Sol-Gel Technologies Ltd, H2 2017 23 Pipeline by Valeant Pharmaceuticals International Inc, H2 2017 24 Dormant Products, H2 2017 53 Dormant Products, H2 2017 (Contd..1), H2 2017 54 Discontinued Products, H2 2017 55
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
